Advanced search
Publication Cover
Scandinavian Cardiovascular Journal Volume 52, 2018 - Issue 4
Submit an article Journal homepage
311
Views
0
CrossRef citations to date
0
Altmetric
Original Article

Dabigatran affects thrombin-dependent platelet aggregation after a week-long therapy

Juraj SokolDepartment of Haematology and Transfusion Medicine, National Centre of Haemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59 Martin, Slovakia; View further author information
,
Frantisek NehajFirst Department of Internal Medicine, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59 Martin, SlovakiaCorrespondence[email protected]
View further author information
,
Jela IvankovaDepartment of Haematology and Transfusion Medicine, National Centre of Haemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59 Martin, Slovakia; View further author information
,
Michal MokanFirst Department of Internal Medicine, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59 Martin, SlovakiaView further author information
,
Marian MokanFirst Department of Internal Medicine, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59 Martin, SlovakiaView further author information
&
Jan StaskoDepartment of Haematology and Transfusion Medicine, National Centre of Haemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Kollarova 2, 036 59 Martin, Slovakia; View further author information
Pages 227-231 | Received 12 Jan 2018, Accepted 10 May 2018, Published online: 29 May 2018

References

  • Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48(1):1–22.
  • Di Nisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353(10):1028–1040.
  • Wändell P, Carlsson AC, Sundquist J, Johansson SE, Bottai M, Sundquist K. Effect of cardiovascular drugs on mortality in atrial fibrillation and chronic heart failure. Scand Cardiovasc J. 2014;48(5):291–298.
  • Maaroos M, Pohjantähti-Maaroos H, Halonen J, Vähämetsä J, Turtiainen J, Rantonen J, Hakala T, Mennander AA, Hartikainen J. New onset postoperative atrial fibrillation and early anticoagulation after cardiac surgery. Scand Cardiovasc J. 2017;51(6):323–326.
  • Wändell P, Carlsson AC, Holzmann MJ, Ärnlöv J, Johansson SE, Sundquist J, Sundquist K. Warfarin treatment and risk of stroke among primary care patients with atrial fibrillation. Scand Cardiovasc J. 2016;50(5-6):311–316.
  • van Ryn J, Hauel N, Waldman L, Wienen W. Dabigatran inhibits both clot-bound and fluid-phase thrombin in vitro: comparison to heparin and hirudin [abstract 570]. Arterioscler Thromb Vasc Biol. 2008;28:e136-e137.
  • Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007;98:155–162.
  • Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
  • Vinholt PJ, Nielsen C, Söderström AC, Brandes A, Nybo M. Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent manner. J Thromb Thrombolysis. 2017;44(2):216–222.
  • Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 medi- ate activation of human platelets by thrombin. J Clin Invest. 1999;103:879–887.
  • Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M, Machin S, British Committee for Standards in Haematology. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol. 2011;155(1):30–44.
  • Li Z, Delaney MK, O’Brien KA, Du X. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol. 2010;30(12):2341–2349.
  • Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016;41(1):206–232.
  • Sreiff MB, Agnelli G, Connors JM, Crowther M, Eichinger S, Lopes R, McBane RD, Moll S, Ansell J. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis. 2016;41(1):32–67.
  • Olivier CB, Weik P, Meyer M, Weber S, Anto-Michel N, Diehl P, Zhou Q, Geisen U, Bode C, Moser M. TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran. Thromb Res. 2016;138:63–68.
  • Perzborn E, Heitmeier S, Buetehorn U, Laux V. Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo. J Thromb Haemost. 2014;12(7):1054–1065.
  • Martischnig AM, Mehilli J, Pollak J, Petzold T, Fiedler AK, Mayer K, Schulz-Schüpke S, Sibbing D, Massberg S, Kastrati A, Sarafoff N. Impact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials). Biomed Res Int. 2015;2015:798486.
  • Nehaj F, Sokol J, Ivankova J, Mokan M, Kovar F, Stasko J, Mokan M. First Evidence: TRAP-Induced Platelet Aggregation Is Reduced in Patients Receiving Xabans. Clin Appl Thromb Hemost. 2017;1:1076029617734310. [Epub ahead of print].
  • Nehaj F, Sokol J, Mokan M, Ivankova J, Mokan M. Thrombin Receptor Agonist Peptide-Induced Platelet Aggregation Is Reduced in Patients Receiving Dabigatran. Clin Appl Thromb Hemost. 2018;24(2):268–272.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.